Advances in the treatment of chronic myeloid leukemia

@inproceedings{Eiring2011AdvancesIT,
  title={Advances in the treatment of chronic myeloid leukemia},
  author={Anna M. Eiring and Jamshid S Khorashad and Kimberly M. Morley and Michael W. Deininger},
  booktitle={BMC medicine},
  year={2011}
}
Although imatinib is firmly established as an effective therapy for newly diagnosed patients with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this minireview we cover recent results of second generation tyrosine kinase inhibitors in newly diagnosed patients, investigate the state of strategies to discontinue therapy and report on new small molecule inhibitors to tackle resistant disease, focusing on agents that target the T315I mutant of BCR-ABL. As a… CONTINUE READING

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

Targeting the Process of c-MYC Stabilization in Chronic Myelogenous Leukemia

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

A Review on Imatinib: A wonder drug in Oncology

VIEW 3 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Conformational control inhibition of the BCR - ABL 1 tyrosine kinase , including the gatekeeper T 315 I mutant , by the switchcontrol inhibitor DCC2036

  • VM Zaleskas, LJ Stewart, RA VanEtten, DL Flynn
  • Cancer Cell
  • 2011

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

VIEW 1 EXCERPT

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

VIEW 1 EXCERPT